Homarine Alkyl Ester Derivatives as Promising Acetylcholinesterase Inhibitors.
Karen G JoãoRomeu António VideiraFátima Paiva-MartinsPatrícia ValentãoDavid M PerreiraPaula Branquinho AndradePublished in: ChemMedChem (2021)
Reversible acetylcholinesterase (AChE) inhibitors are key therapeutic tools to modulate the cholinergic connectivity compromised in several degenerative pathologies. In this work, four alkyl esters of homarine were synthesized and screened by using Electrophorus electricus AChE and rat brain AChE-rich fraction. Results showed that all homarine alkyl esters are able to inhibit AChE by a competitive inhibition mode. The effectiveness of AChE inhibition increases with the alkyl side chain length of the homarine esters, being HO-C16 (IC50 =7.57±3.32 μM and Ki =18.96±2.28 μM) the most potent inhibitor. The fluorescence quenching studies confirmed that HO-C16 is the compound with higher selectivity and affinity for the tryptophan residues in the catalytic active site of AChE. Preliminary cell viability studies showed that homarine esters display no toxicity for human neuronal SH-SY5Y cells. Thus, the long-chain homarine esters emerge as new anti-cholinesterase agents, with potential to be considered for therapeutic applications development.
Keyphrases
- ionic liquid
- induced apoptosis
- randomized controlled trial
- endothelial cells
- systematic review
- multiple sclerosis
- neoadjuvant chemotherapy
- single molecule
- squamous cell carcinoma
- radiation therapy
- climate change
- case control
- cell death
- induced pluripotent stem cells
- risk assessment
- subarachnoid hemorrhage
- lymph node
- endoplasmic reticulum stress
- quantum dots
- functional connectivity